The 2017-2018 recommendations by the Advisory Committee on Immunization Practices (ACIP) mentions routine annual influenza vaccination for everyone aged 6 months and older with either inactivated influenza vaccine
(IIV) or recombinant influenza vaccine
In particular, Seqirus will present clinical data on a seasonal adjuvanted influenza vaccine
, including studies that assessed immune response against homologous and heterologous influenza strains and cross-reactive antibodies in young children (6 months old up to 6 years old).1,2 The company will also feature studies on a pandemic adjuvanted, cell-based H5N1 vaccine that examined immune responses against heterologous A (H5N1) strains in young children (6 months to 17 years old), adults (18 to < 65 years) and elderly populations (65 years and older), as well as a retrospective analysis on the level of antigenic similarity of cell-based versus egg-based influenza vaccine
reference strains and circulating influenza B viruses.3,4,5
Every year, injectable inactivated influenza vaccine
(IIV) has a standard expiration date of June 30 for the upcoming influenza season (i.e., July 1-June 30 of the following year).
An agreement with the Global Health Corporation as part of the Influenza Vaccine
Partnership Project (PIVI) was signed, and 70,000 doses of influenza vaccine
for more than $189,000 were received, the statement said.
THE FOOD AND DRUG ADMINISTRATION has extended the indication for a quadrivalent influenza vaccine
(Afluria, marketed by Seqirus) to include infants and younger children.
M2 EQUITYBITES-October 24, 2018-Seqirus passes US FDA approval for AFLURIA QUADRIVALENT (Influenza Vaccine
) in the US
Global Banking News-October 24, 2018-Seqirus passes US FDA approval for AFLURIA QUADRIVALENT (Influenza Vaccine
) in the US
M2 PHARMA-October 24, 2018-Seqirus passes US FDA approval for AFLURIA QUADRIVALENT (Influenza Vaccine
) in the US
There were 171 pediatric deaths attributed to influenza, and more than three-quarters of vaccine-eligible children who died from influenza this season had not received influenza vaccine
240 crore research programme to develop a Next Generation Influenza Vaccine
to protect citizens worldwide.
Research offers clues for improved influenza vaccine